ARV Dosing for Renal or Hepatic Insufficiency Appendix B: Drug Characteristics Tables Adult and Adolescent ARV

The Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents is accepting nominations for new scientific/clinical members with expertise in HIV medicine, as well as nominations for a community representative. Nominations should be submitted to Alice Pau, Pharm.D., electronically (apau@niaid.nih.gov) by no later than January 10, 2020.

For more information on the scientific/clinical member nomination requirements, please read this news announcement.

For more information on the community member nomination requirements, please read this news announcement.

Brief Version

Full Version

Appendix B: Drug Characteristics Tables

Antiretroviral Dosing Recommendations in Patients with Renal or Hepatic Insufficiency

Last Updated: July 10, 2019; Last Reviewed: July 10, 2019

Appendix B, Table 10. Antiretroviral Dosing Recommendations in Patients with Renal or Hepatic Insufficiency

See the reference section at the end of this table for CrCl calculation formulas and criteria for Child-Pugh classification.

Appendix B, Table 10. Antiretroviral Dosing Recommendations in Patients with Renal or Hepatic Insufficiency

Generic Name
(Abbreviation)
Trade Name

Usual Daily Dose^a

Dosing in Patients with Renal Insufficiency^b

Dosing in Patients with Hepatic Impairment

NRTIs
Stribild should not be initiated in patients with CrCl <70 mL/min. The following FDC tablets are not recommended in patients with CrCl <50 mL/min: Atripla, Combivir, Complera, Delstrigo, Dovato, Epzicom, Triumeq, or Trizivir. Biktarvy, Descovy, Odefsey, Symtuza, and Truvada are not recommended in patients with CrCl <30 mL/min.

Abacavir
(ABC)
Ziagen

ABC 300 mg PO twice daily
or
ABC 600 mg PO once daily

No dose adjustment necessary.

Child-Pugh Class A: ABC 200 mg PO twice daily (use oral solution)

Child-Pugh Class B or C: Contraindicated

Didanosine EC
(ddI)
Videx EC

Body Weight ≥60 kg:

ddI 400 mg PO once daily

Body Weight <60 kg:

ddI 250 mg PO once daily

Once-Daily Dose by Body Weight
CrCl (mL/min)	≥60 kg	<60 kg
30–59	200 mg	125 mg
10–29	125 mg	125 mg
<10, HD,^c or CAPD	125 mg	75 mg oral solution

No dose adjustment necessary.

Didanosine Oral Solution
(ddI)
Videx

Body Weight ≥60 kg:

ddI 200 mg PO twice daily, or
ddI 400 mg PO once daily

Body Weight <60 kg:

ddI 250 mg PO once daily, or
ddI 125 mg PO twice daily

Once-Daily Dose by Body Weight
CrCl (mL/min)	≥60 kg	<60 kg
30–59	200 mg	150 mg
10–29	150 mg	100 mg
<10, HD,^c or CAPD	100 mg	75 mg

No dose adjustment necessary.

Emtricitabine
(FTC)
Emtriva

FTC 200 mg oral capsule once daily
or
FTC 240 mg (24 mL) oral solution once daily

Dose by Formulation
CrCl (mL/min)	Capsule	Solution
30–49	200 mg q48h	120 mg q24h
15–29	200 mg q72h	80 mg q24h
<15 or on HD^c	200 mg q96h	60 mg q24h

No dose recommendation.

Lamivudine
(3TC)
Epivir

3TC 300 mg PO once daily
or
3TC 150 mg PO twice daily

CrCl (mL/min)	Dose
30–49	150 mg q24h
15–29	1 x 150 mg, then 100 mg q24h
5–14	1 x 150 mg, then 50 mg q24h
<5 or on HD^c	1 x 50 mg, then 25 mg q24h

No dose adjustment necessary.

Stavudine
(d4T)
Zerit

Body Weight ≥60 kg:

d4T 40 mg PO twice daily

Body Weight <60 kg:

d4T 30 mg PO twice daily

Dose by Body Weight
CrCl (mL/min)	≥60 kg	<60 kg
26–50	20 mg q12h	15 mg q12h
10–25 or on HD^c	20 mg q24h	15 mg q24h

No dose recommendation.

Tenofovir Alafenamide/ Emtricitabine
(TAF/FTC)
Descovy

TAF for HIV treatment is only available as a component of FDC tablets (i.e., Descovy, Genvoya, Odefsey, Biktarvy, and Symtuza).

TAF 10 mg PO daily with EVG/c (Genvoya) or DRV/c (Symtuza)

TAF 25 mg PO daily in other FDC tablets

CrCl (ml/min)	Dose
<30 or on HD^c	Not recommended

Child-Pugh Class A or B: No dose adjustment

Child-Pugh Class C: No dose recommendation

Tenofovir Disoproxil Fumarate
(TDF)
Viread

TDF 300 mg PO once daily

CrCl (mL/min)	Dose
30–49	300 mg q48h
10–29	300 mg twice weekly (q72–96h)
<10 and not on HD	No recommendation
On HD^c	300 mg q7d

No dose adjustment necessary.

Tenofovir Disoproxil Fumarate/ Emtricitabine
(TDF/FTC)
Truvada

One tablet PO once daily

CrCl (mL/min)	Dose
30–49	One tablet q48h
<30 or on HD	Not recommended

No dose recommendation.

Tenofovir Disoproxil Fumarate/ Lamivudine
(TDF/3TC)
Cimduo

One tablet PO once daily

CrCl (mL/min)	Dose
<50 or on HD	Not recommended

No dose recommendation.

Zidovudine
(ZDV)
Retrovir

ZDV 300 mg PO twice daily

CrCl (mL/min)	Dose
<15 or on HD^c	100 mg three times a day or 300 mg once daily

No dose recommendation.

NNRTIs

Doravirine
(DOR)
Pifeltro

One tablet PO once daily

No dose adjustment required in mild, moderate, or severe renal impairment. Has not been studied in ESRD or HD.

Child-Pugh Class A or B: No dose adjustment

Child-Pugh Class C: Not studied

Doravirine/Tenofovir Disoproxil Fumarate/Lamivudine
(DOR/TDF/3TC)
Delstrigo

One tablet PO once daily

Not recommended if CrCl <50 mL/min.

Child-Pugh Class A or B: No dose adjustment

Child-Pugh Class C: Not studied

Efavirenz
(EFV)
Sustiva

EFV 600 mg PO once daily on an empty stomach, preferably at bedtime

No dose adjustment necessary.

No dose recommendation; use with caution in patients with hepatic impairment.

Efavirenz/Tenofovir Disoproxil Fumarate/Emtricitabine
(EFV/TDF/FTC)
Atripla

One tablet once daily on an empty stomach, preferably at bedtime

Not recommended if CrCl <50 mL/min. Instead, use the individual drugs and adjust TDF and FTC doses according to CrCl level.

No dose recommendation; use with caution in patients with hepatic impairment.

Efavirenz 600 mg/Tenofovir Disoproxil Fumarate/Lamivudine
(EFV/TDF/3TC)
Symfi

One tablet once daily on an empty stomach, preferably at bedtime

Not recommended if CrCl <50 mL/min or if patient is on HD. Instead, use the individual drugs and adjust TDF and 3TC doses according to CrCl level.

Not recommended for patients with moderate or severe hepatic impairment. Use caution in patients with mild hepatic impairment.

Efavirenz 400 mg/Tenofovir Disoproxil Fumarate/Lamivudine
(EFV/TDF/3TC)
Symfi Lo

One tablet once daily on an empty stomach, preferably at bedtime

Not recommended if CrCl <50 mL/min or if patient is on HD. Instead, use the individual drugs and adjust TDF and 3TC doses according to CrCl level.

Not recommended for patients with moderate or severe hepatic impairment. Use caution in patients with mild hepatic impairment.

Etravirine
(ETR)
Intelence

ETR 200 mg PO twice daily

No dose adjustment necessary.

Child-Pugh Class A or B: No dose adjustment

Child-Pugh Class C: No dose recommendation

Nevirapine
(NVP)
Viramune or Viramune XR

NVP 200 mg PO twice daily
or
NVP 400 mg PO once daily (using Viramune XR formulation)

No dose adjustment for patients with renal impairment.

Patients on HD should receive an additional dose of NVP 200 mg following each dialysis treatment.

Child-Pugh Class A: No dose adjustment

Child-Pugh Class B or C: Contraindicated

Rilpivirine
(RPV)
Edurant

RPV 25 mg PO once daily

No dose adjustment necessary.

Child-Pugh Class A or B: No dose adjustment

Child-Pugh Class C: No dose recommendation

Rilpivirine/Tenofovir Alafenamide/Emtricitabine
(RPV/TAF/FTC)
Odefsey

One tablet PO once daily

Not recommended if CrCl <30 mL/min.

Child-Pugh Class A or B: No dose adjustment

Child-Pugh Class C: No dose recommendation

Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine
(RPV/TDF/FTC)
Complera

One tablet PO once daily

Not recommended if CrCl <50 mL/min. Instead, use the individual drugs and adjust TDF and FTC doses according to CrCl level.

Child-Pugh Class A or B: No dose adjustment

Child-Pugh Class C: No dose recommendation

Rilpivirine/Dolutegravir
(RPV/DTG)
Juluca

One tablet PO once daily with food

No dose adjustment necessary.

In patients with CrCl <30 mL/min, monitor closely for adverse effects.

Child-Pugh Class A or B: No dose adjustment

Child-Pugh Class C: No dose recommendation

PIs

Atazanavir
(ATV)
Reyataz

ATV 400 mg PO once daily
or
(ATV 300 mg plus RTV 100 mg) PO once daily

No dose adjustment for patients with renal dysfunction who do not require HD.

In ARV-Naive Patients on HD:

(ATV 300 mg plus RTV 100 mg) once daily

In ARV-Experienced Patients on HD:

ATV and ATV/r are not recommended

Child-Pugh Class A: No dose adjustment

Child-Pugh Class B: ATV 300 mg once daily (unboosted) for ARV-naive patients only

Child-Pugh Class C: Not recommended

RTV boosting is not recommended in patients with hepatic impairment.

Atazanavir/Cobicistat
(ATV/c)
Evotaz

One tablet PO once daily

If Used with TDF:

Not recommended if CrCl <70 mL/min

Not recommended in patients with hepatic impairment.

Darunavir
(DRV)
Prezista

In ARV-Naive Patients and ARV-Experienced Patients with No DRV Resistance Mutations:

(DRV 800 mg plus RTV 100 mg) PO once daily with food

In ARV-Experienced Patients with at Least One DRV Resistance Mutation:

(DRV 600 mg plus RTV 100 mg) PO twice daily

No dose adjustment necessary.

In Patients with Mild-to-Moderate Hepatic Impairment: No dose adjustment

In Patients with Severe Hepatic Impairment: Not recommended

Darunavir/Cobicistat
(DRV/c)
Prezcobix

One tablet PO once daily

If Used with TDF:

Not recommended if CrCl <70 mL/min

Child-Pugh Class A or B: No dose adjustment

Child-Pugh Class C: Not recommended

Darunavir/Cobicistat/Tenofovir Alafenamide/Emtricitabine
(DRV/c/TAF/FTC)
Symtuza

One tablet PO once daily

Not recommended if CrCl <30 mL/min.

Not recommended for patients with severe hepatic impairment.

Fosamprenavir
(FPV)
Lexiva

1,400 mg PO twice daily
or
(FPV 1,400 mg plus RTV 100–200 mg) PO once daily
or
(FPV 700 mg plus RTV 100 mg) PO twice daily

No dose adjustment necessary.

In PI-Naive Patients Only (without RTV)
Child-Pugh Score 5–9:

FPV 700 mg twice daily

Child-Pugh Score 10–15:

FPV 350 mg twice daily

In PI-Naive or PI-Experienced Patients
Child-Pugh Score 5–6:

FPV 700 mg twice daily plus RTV 100 mg once daily

Child-Pugh Score 7–9:

FPV 450 mg twice daily plus RTV 100 mg once daily

Child-Pugh Score 10–15:

FPV 300 mg twice daily plus RTV 100 mg once daily

Indinavir
(IDV)
Crixivan

IDV 800 mg PO q8h

No dose adjustment necessary.

In Patients with Mild-to-Moderate Hepatic Insufficiency Due to Cirrhosis: IDV 600 mg q8h

Lopinavir/Ritonavir
(LPV/r)
Kaletra

(LPV/r 400 mg/100 mg) PO twice daily
or
(LPV/r 800 mg/200 mg) PO once daily

Avoid once-daily dosing in patients on HD.

No dose recommendation; use with caution in patients with hepatic impairment.

Nelfinavir
(NFV)
Viracept

NFV 1,250 mg PO twice daily

No dose adjustment necessary.

In Patients with Mild Hepatic Impairment: No dose adjustment

In Patients with Moderate-to-Severe Hepatic Impairment: Not recommended

Ritonavir
(RTV)
Norvir

As a PI-Boosting Agent:

RTV 100–400 mg per day

No dose adjustment necessary.

Refer to recommendations for the primary PI.

Saquinavir
(SQV)
Invirase

(SQV 1,000 mg plus RTV 100 mg) PO twice daily

No dose adjustment necessary.

In Patients with Mild-to-Moderate Hepatic Impairment: Use with caution

In Patients with Severe Hepatic Impairment: Contraindicated

Tipranavir
(TPV)
Aptivus

(TPV 500 mg plus RTV 200 mg) PO twice daily

No dose adjustment necessary.

Child-Pugh Class A: Use with caution

Child-Pugh Class B or C: Contraindicated

INSTIs

Bictegravir/ Tenofovir Alafenamide/ Emtricitabine
(BIC/TAF/FTC)
Biktarvy

One tablet once daily

Not recommended for use in patients with CrCl <30 mL/min.

Child-Pugh Class A or B: No dose adjustment

Child-Pugh Class C: Not recommended

Dolutegravir
(DTG)
Tivicay

DTG 50 mg once daily
or
DTG 50 mg twice daily

No dose adjustment necessary.

Child-Pugh Class A or B: No dose adjustment

Child-Pugh Class C: Not recommended

Dolutegravir/ Abacavir/ Lamivudine
(DTG/ABC/3TC)
Triumeq

One tablet once daily

Not recommended if CrCl <50 mL/min. Instead, use the individual drugs and adjust 3TC dose according to CrCl.

Child-Pugh Class A: Patients with mild hepatic impairment require a dose reduction of ABC. Use the individual drugs instead of the FDC tablet in these patients.

Child-Pugh Class B or C: Contraindicated due to the ABC component

Dolutegravir/ Rilpivirine
(DTG/RPV)
Juluca

One tablet PO once daily with food

No dose adjustment necessary.

In patients with CrCl <30 mL/min, monitor closely for adverse effects.

Child-Pugh Class A or B: No dose adjustment

Child-Pugh Class C: No dose recommendation

Elvitegravir/ Cobicistat/ Tenofovir Alafenamide/ Emtricitabine
(EVG/c/TAF/FTC)
Genvoya

One tablet once daily

In Patients on Chronic HD:

One tablet once daily. On dialysis days, administer after dialysis.

Not recommended in patients with CrCl <30 mL/min or ≤15 mL/min who are not receiving chronic HD.

In Patients with Mild-to-Moderate Hepatic Insufficiency: No dose adjustment necessary

In Patients with Severe Hepatic Insufficiency: Not recommended

Elvitegravir/ Cobicistat/ Tenofovir Disoproxil Fumarate/ Emtricitabine
(EVG/c/TDF/FTC)
Stribild

One tablet once daily

EVG/c/TDF/FTC should not be initiated in patients with CrCl <70 mL/min.

Discontinue EVG/c/TDF/FTC if CrCl declines to <50 mL/min while patient is on therapy.

In Patients with Mild-to-Moderate Hepatic Insufficiency: No dose adjustment necessary

In Patients with Severe Hepatic Insufficiency: Not recommended

Raltegravir
(RAL)
Isentress
Isentress HD

RAL 400 mg twice daily (using Isentress formulation)
or
RAL 1,200 mg once daily (using Isentress HD formulation only)

No dose adjustment necessary.

In Patients with Mild-to-Moderate Hepatic Insufficiency: No dose adjustment necessary

In Patients with Severe Hepatic Insufficiency: No recommendation

Fusion Inhibitor

Enfuvirtide
(T-20)
Fuzeon

T-20 90 mg SQ twice daily

No dose adjustment necessary.

CCR5 Antagonist

Maraviroc
(MVC)
Selzentry

The recommended dose differs based on concomitant medications and potential for drug-drug interactions. See Appendix B, Table 8 for detailed dosing information.

In Patients with CrCl <30 mL/min or Patients Who Are on HD
Without Potent CYP3A Inhibitors or Inducers:

MVC 300 mg twice daily; reduce to 150 mg twice daily if postural hypotension occurs

With Potent CYP3A Inducers or Inhibitors:

Not recommended

No dose recommendations. MVC concentrations will likely be increased in patients with hepatic impairment.

CD4 Post-Attachment Inhibitor

Ibalizumab
(IBA)
Trogarzo

Loading dose of IBA 2,000 mg IV, followed by a maintenance dose of IBA 800 mg IV every 2 weeks

No dose adjustment recommended.

No recommendation.

^a Refer to Appendix B, Tables 1–9 for additional dosing information.

^b Including patients who are on CAPD and HD.

^c On dialysis days, the patient should take the dose after the HD session.

Key: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; ATV = atazanavir; ATV/c = atazanavir/cobicistat; ATV/r = atazanavir/ritonavir; BIC = bictegravir; CAPD = chronic ambulatory peritoneal dialysis; COBI = cobicistat; CrCl = creatinine clearance; CYP = cytochrome P; d4T = stavudine; ddI = didanosine; DLV = delavirdine; DOR = doravirine; DRV = darunavir; DRV/c = darunavir/cobicistat; DTG = dolutegravir; EC = enteric coated; EFV = efavirenz; ESRD = end stage renal disease; ETR = etravirine; EVG = elvitegravir; EVG/c = elvitegravir/cobicistat; FDC = fixed-dose combination; FPV = fosamprenavir; FTC = emtricitabine; HD = hemodialysis; IBA = ibalizumab; IDV = indinavir; INSTI = integrase strand transfer inhibitor; IV = intravenous; LPV = lopinavir; LPV/r = lopinavir/ritonavir; MVC = maraviroc; NFV = nelfinavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; PO = orally; q(n)d = every (n) days; q(n)h = every (n) hours; RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; SQ = subcutaneous; SQV = saquinavir; T-20 = enfuvirtide; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; TPV = tipranavir; XR = extended release; ZDV = zidovudine

Appendix B, Table 10. Antiretroviral Dosing Recommendations in Patients with Renal or Hepatic Insufficiency

Click here to view this table.

Creatinine Clearance Calculation
Male: (140 − age in years) x (weight in kg) 72 x (serum creatinine)	Female: (140 - age in years) x (weight in kg) x (0.85) 72 x (serum creatinine)

Child-Pugh Score
Component	Points Scored
Component	1	2	3
Encephalopathy^a	None	Grade 1–2	Grade 3–4
Ascites	None	Mild or controlled by diuretics	Moderate or refractory despite diuretics
Albumin	>3.5 g/dL	2.8–3.5 g/dL	<2.8 g/dL
Total bilirubin, or	<2 mg/dL (<34 µmol/L)	2–3 mg/dL (34–50 µmol/L)	>3 mg/dL (>50 µmol/L)
Modified total bilirubin^b	<4 mg/dL	4–7 mg/dL	>7 mg/dL
Prothrombin time (seconds prolonged), or	<4	4–6	>6
International normalized ratio (INR)	<1.7	1.7–2.3	>2.3
^a Encephalopathy Grades Grade 1: Mild confusion, anxiety, restlessness, fine tremor, slowed coordination Grade 2: Drowsiness, disorientation, asterixis Grade 3: Somnolent but rousable, marked confusion, incomprehensible speech, incontinence, hyperventilation Grade 4: Coma, decerebrate posturing, flaccidity ^b Modified total bilirubin is used for patients who have Gilbert’s syndrome or who are taking indinavir or atazanavir.

**Child-Pugh Classification Scores**
Child-Pugh Classification	Total Child-Pugh Score^a
Class A	5–6 points
Class B	7–9 points
Class C	>9 points
^a Sum of points for each component of the Child-Pugh Score

Download Guidelines

Section Only PDF (354 KB)
Full Guideline PDF (4.7 MB)
Recommendations Only PDF (88.9 KB)
Tables Only PDF (563 KB)

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV

Download Guidelines

Related Content

Appendix B: Drug Characteristics Tables

Antiretroviral Dosing Recommendations in Patients with Renal or Hepatic Insufficiency

Download Guidelines

Related Content

QUICK LINKS